Prognostic factors in metastatic malignant melanoma. An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972-1992

Oncology

Volumn 55, Issue 1, 1997, Pages 59-64

  Falkson, Carla I ^a   Falkson, Hendre C ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Malignant metastatic melanoma; Prognostic factors

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE; FOTEMUSTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT FAILURE; ANALYSIS OF VARIANCE; LIFE TABLE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SKIN TUMOR; SURVIVAL; TIME;

ADULT; AGED; ANALYSIS OF VARIANCE; FEMALE; HUMANS; LIFE TABLES; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE;

EID: 0030721721     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011836     Document Type: Article

References (18)

1. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 1982;38:29-41.
2. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
3. Budman DR, Camacho E, Wittes RE: The current causes of death in patients with malignant melanoma. Eur J Cancer 1978;14:327-330.
4. Patel JK, Didolkar MS, Pickren JW, Moore RH: Metastatic pattern of malignant melanoma: A study of 216 autopsy cases. Am J Surg 1978;135:807-810.
5. Balch CM, Soon S-J, Murad TM, Smith JW, Maddox WA, Durant JR: A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126-134.
6. Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev 1974;1:285-304.
7. Luce JK: Chemotherapy of melanoma. Sem Oncol 1975;2:179-185.
8. Einhorn LH, Burgess MA, Vallejos C, Bodey GP, Gutterman J, Mavligit G, Hersh EM, Luce JK, Frei E, Freireich EJ, Gottlieb JA: Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 1974;34:1995-2004.
9. Ryan L, Kramar A, Borden E: Prognostic factors in metastatic melanoma. Cancer 1993;71:2995-3005.
10. Hena MA, Emrich LJ, Nambisan RN, Karakousis CP: Effect of surgical treatment on stage IV melanoma. Am J Surg 1987;153:270-275.
11. Costanza ME, Nathanson L, Schoenfeld D, Wolter J, Colsky J, Regelson W, Cunningham T, Sedransk N: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 1977;40:1010-1015.
12. Markman M: Survival in stage III malignant melanoma (letter). Lancet 1980;ii:1090.
13. Amer MH, Al-Sarraf M, Vaitkevicius VK: Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 1979;149:687-692.
14. Carbone PP, Costello W: Eastern Cooperative Oncology Group studies with DTIC (NSC45388). Cancer Treat Rep 1976;60:193-198.
15. Rampen F: Malignant melanoma: Sex differences in survival after evidence of distant metastases. Br J Cancer 1980;42:52-57.
16. Karakousis CP, Temple DF, Moorse MS, Ambrus JL: Prognostic parameters in recurrent malignant melanoma. Cancer 1983;52:575-579.
17. Presant CA, Bartolucci AA: Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group Experience. Cancer 1982;49:2192-2196.
18. Yarnold JR,Cochrane JP: Malignant melanoma: Significance of disease-free interval. Br J Radiol 1980;53:1068-1070.